1. Where Aspergillosis Comes From. (2021, January 8, 2021).
  2. Kwon-Chung, K. J., & Sugui, J. A. (2013). Aspergillus fumigatus—what makes the species a ubiquitous human fungal pathogen? PLoS Pathog, 9(12), e1003743.
  3. Kousha, M., Tadi, R., & Soubani, A. O. (2011). Pulmonary aspergillosis: a clinical review. Eur Respir Rev, 20(121), 156-174.
  4. Koehler, P., Bassetti, M., Chakrabarti, A., et al. (2021). Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis, 21(6), e149-e162. S1473-3099(20)30847-1
  5. Taccone, F. S., Van den Abeele, A. M., Bulpa, P., et al. (2015). Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit Care, 19(1), 7.
  6. Kosmidis, C., & Denning, D. W. (2015). The clinical spectrum of pulmonary aspergillosis. Thorax, 70(3), 270-277.
  7. Chabi, M. L., Goracci, A., Roche, N., et al. (2015). Pulmonary aspergillosis. Diagn Interv Imaging, 96(5), 435-442.
  8. Denning, D. W., Cadranel, J., Beigelman-Aubry, C., et al. (2016). Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J, 47(1), 45-68.
  9. Patterson, T. F. (2022). Treatment and prevention of invasive aspergillosis. In C. A. Kauffman (Ed.). UpToDate.
  10. CRESEMBA® (isavuconazonium sulfate) capsules, injection [prescribing information]. Northbrook, IL: Astellas Pharma US; November 2022. Accessed on February 16, 2023.
  11. Cronin, S., & Chandrasekar, P. H. (2010). Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother, 65(3), 410-416.
  12. Murray, A., Cass, L., Ito, K., et al. (2020). PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections. J Fungi (Basel), 6(4).
  13. Vallabhaneni, S., Benedict, K., Derado, G., et al. (2017). Trends in Hospitalizations Related to Invasive Aspergillosis and Mucormycosis in the United States, 2000-2013. Open Forum Infect Dis, 4(1), ofw268.
  14. Colley, T., Alanio, A., Kelly, S. L., et al. (2017). In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. Antimicrob Agents Chemother, 61(5).
  15. Logan, A., Wolfe, A., & Williamson, J. C. (2022). Antifungal Resistance and the Role of New Therapeutic Agents. Curr Infect Dis Rep, 24(9), 105-116.
  16. Ito, K. (2022). Inhaled antifungal therapy: benefits, challenges, and clinical applications. Expert Opin Drug Deliv, 19(7), 755-769.
  17. Cass, L., Murray, A., Davis, A., et al. (2021). Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent. Pharmacol Res Perspect, 9(1), e00690.
  18. Pagani, N., Armstrong-James, D., & Reed, A. (2020). Successful salvage therapy for fungal bronchial anastomotic infection after -lung transplantation with an inhaled triazole anti-fungal PC945. J Heart Lung Transplant, 39(12), 1505-1506.
  19. Wenzler, E., Fraidenburg, D. R., Scardina, T., et al. (2016). Inhaled Antibiotics for Gram-Negative Respiratory Infections. Clin Microbiol Rev, 29(3), 581-632.
  20. Kimura, G., Nakaoki, T., Colley, T., et al. (2017). In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice. Antimicrob Agents Chemother, 61(9).
  21. MHRA. (2014). The supply of unlicensed medicinal products (“specials”). Retrieved from
  22. Singh, S., Moore, L. S. P., Mughal, N., et al. (2023). Novel inhaled antifungal for pseudomembranous Aspergillus tracheobronchitis complicating connective tissue disease. Thorax, 78(1), 110-111.


  • About Aspergillosis Image source: Prasad, A., Agarwal, K., Deepak, D., et al. (2016). Pulmonary Aspergillosis: What CT can Offer Before it is too Late! J Clin Diagn Res, 10(4), TE01-05.
  • Data on file
  • Zhou, L. H., Jiang, Y. K., Li, R. Y., et al. (2020). Risk-Based Estimate of Human Fungal Disease Burden, China. Emerg Infect Dis, 26(9), 2137-2147.
Scroll to Top